.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Federal Trade Commission
Accenture
Baxter
Cipla
Chinese Patent Office
Julphar
Boehringer Ingelheim
Teva
US Army

Generated: December 16, 2017

DrugPatentWatch Database Preview

TRICOR Drug Profile

« Back to Dashboard

When do Tricor patents expire, and when can generic versions of Tricor launch?

Tricor is a drug marketed by Abbvie and Abbvie Inc and is included in three NDAs. There are nine patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and fifty-four patent family members in forty-two countries.

The generic ingredient in TRICOR is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.
Drug patent expirations by year for TRICOR

Medical Subject Heading (MeSH) Categories for TRICOR

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
AbbvieTRICOR (MICRONIZED)fenofibrateCAPSULE;ORAL019304-003Jun 30, 1999DISCNYesNo► Subscribe► Subscribe► Subscribe
AbbvieTRICOR (MICRONIZED)fenofibrateCAPSULE;ORAL019304-004Jun 30, 1999DISCNYesNo► Subscribe► Subscribe► Subscribe
AbbvieTRICORfenofibrateTABLET;ORAL021656-001Nov 5, 2004ABRXYesNo► Subscribe► SubscribeY► Subscribe
Abbvie IncTRICORfenofibrateTABLET;ORAL021203-001Sep 4, 2001DISCNYesNo► Subscribe► SubscribeY► Subscribe
Abbvie IncTRICORfenofibrateTABLET;ORAL021203-003Sep 4, 2001DISCNYesNo► Subscribe► Subscribe► Subscribe
AbbvieTRICORfenofibrateTABLET;ORAL021656-001Nov 5, 2004ABRXYesNo► Subscribe► SubscribeY► Subscribe
AbbvieTRICORfenofibrateTABLET;ORAL021656-001Nov 5, 2004ABRXYesNo► Subscribe► SubscribeY► Subscribe
AbbvieTRICORfenofibrateTABLET;ORAL021656-002Nov 5, 2004ABRXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie IncTRICORfenofibrateTABLET;ORAL021203-001Sep 4, 2001DISCNYesNo► Subscribe► Subscribe► Subscribe
AbbvieTRICORfenofibrateTABLET;ORAL021656-002Nov 5, 2004ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TRICOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie IncTRICORfenofibrateTABLET;ORAL021203-003Sep 4, 2001► Subscribe► Subscribe
Abbvie IncTRICORfenofibrateTABLET;ORAL021203-001Sep 4, 2001► Subscribe► Subscribe
AbbvieTRICORfenofibrateTABLET;ORAL021656-001Nov 5, 2004► Subscribe► Subscribe
AbbvieTRICORfenofibrateTABLET;ORAL021656-002Nov 5, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for TRICOR

Drugname Dosage Strength RLD Submissiondate
fenofibrateTablets48 mgTricor7/1/2008
fenofibrateTablets145 mgTricor10/19/2007

Non-Orange Book Patents for Tradename: TRICOR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,927,627Nanoparticulate fibrate formulations► Subscribe
7,695,739In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions► Subscribe
6,316,029 Rapidly disintegrating solid oral dosage form► Subscribe
7,998,507Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors► Subscribe
7,459,283Nanoparticulate compositions having lysozyme as a surface stabilizer► Subscribe
7,198,795In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions► Subscribe
6,596,317 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it► Subscribe
8,236,352Glipizide compositions► Subscribe
8,309,136In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions► Subscribe
6,428,814 Bioadhesive nanoparticulate compositions having cationic surface stabilizers► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: TRICOR

Country Document Number Estimated Expiration
Argentina040110► Subscribe
Eurasian Patent Organization023686► Subscribe
European Patent Office1800666► Subscribe
Canada2488499► Subscribe
Spain2359298► Subscribe
Japan4776229► Subscribe
South Korea20120057664► Subscribe
Brazil9806738► Subscribe
Russian Federation2238089► Subscribe
Canada2219475► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Moodys
AstraZeneca
Medtronic
Express Scripts
Chinese Patent Office
Federal Trade Commission
Mallinckrodt
Daiichi Sankyo
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot